Interleukin 2 therapy: current role in surgical oncological practice

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Recombinant interleukin 2 (rIL-2) offers potential in treating malignant diseases by stimulating anti-tumor immune responses.
• Current clinical application of rIL-2 shows limited response rates, with only 30-40% of patients experiencing tumor volume reduction.

Purpose of the Study:

• To evaluate the efficacy of rIL-2-based treatment schedules in delaying disease progression and improving overall survival compared to standard therapies.
• To determine the optimal therapeutic regimens and combinations for rIL-2 in various tumor types through randomized clinical trials.

Main Methods:

• The study emphasizes the need for randomized clinical trials to precisely evaluate rIL-2's role.
• Ongoing studies aim to provide further insights into the beneficial effects of rIL-2 immunotherapy.

Main Results:

• The precise impact of rIL-2 on delaying disease progression and overall survival compared to standard treatments remains unclear.
• Human therapeutic results with rIL-2 have been selective and less beneficial than those observed in experimental animal models.

Conclusions:

• Randomized clinical trials are essential to clarify the role of rIL-2 in cancer therapy and establish optimal treatment protocols.
• Further basic research is required to understand the mechanisms of rIL-2's anti-tumor effects and the reasons for its selective efficacy in humans.